2024-06-13 11:33:07 ET
Summary
- C4 Therapeutics focused on protein degraders, with recent financial updates and guidance for 2024 catalysts.
- The pipeline includes Cemsidomide for multiple myeloma and CFT1946 for melanoma, with ongoing dose escalation trials.
- Financially, CCCC reported $279.6 million in current assets, with a cash runway of approximately 9 to 10 quarters.
Topline Summary and Update
C4 Therapeutics ( CCCC ) is a developmental biotech focused on commercialization of protein degraders that I have now covered twice in the past year. In my last outing , I felt that the then-new partnership with Merck KGaA (MRK), which brought an infusion of cash and gravity to the pipeline, was a big step in the right direction, but not the catalyst that would push me to buy just yet. It has since undergone a bit of a boom and bust cycle, and at the time of writing, the company's valuation is testing pre-deal lows....
Read the full article on Seeking Alpha
For further details see:
C4 Therapeutics: Losing Steam And Presenting An Opportunity